89bio, Inc. ETNB
14.84 0.00 (+0.00%)
At closeOct 30, 2025, 4:00 PM EDT
14.84 Day range 14.84
52-week range unavailable
- YTD
- +89.77%
- 1 year
- +85.73%
- Market cap
- 2.20B
- Shares out
- 148.49M
- YTD return
- +89.77%
- 1-year return
- +85.73%
- Volume
- 38.51M
- Open
- 14.84
- Previous close
- 14.84
- Day's range
- 14.84 – 14.84
- Analysts
- Buy
- Price target
- 30.38 (+104.7%)
No chart data for this range yet.
Key statistics
- Enterprise value
- 1.68B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -257.73M
- Total cash
- 561.16M
- Total debt
- 37.62M
- Return on equity
- -86.86%
- Short % of float
- 6.30%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: buy
Buy
Price target (mean) 30.38 +104.7% upside
Now 14.84
- Target (low)
- 14.50
- Target (mean)
- 30.38
- Target (high)
- 55.00
Ratings (0m) 6 2 buy · 4 hold · 0 sell
- Strong buy0
- Buy2
- Hold4
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
ETNB Revenue — quarterly 0
ETNB Net income — quarterly -111.50M
ETNB EPS — quarterly -0.71
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 19, 2025 | Raymond James | down | Outperform | Market Perform |
| Sep 19, 2025 | Wolfe Research | down | Outperform | Peer Perform |
| Sep 19, 2025 | HC Wainwright & Co. | down | Buy | Neutral |
| Aug 25, 2025 | B of A Securities | main | Buy | Buy |
| Aug 8, 2025 | RBC Capital | main | Sector Perform | Sector Perform |
| Mar 14, 2025 | Goldman Sachs | init | — | Neutral |
About 89bio, Inc.
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly known as The company was founded in 2018 and is based in San Francisco, California. As of October 29, 2025, 89bio, Inc. operates as a subsidiary of Roche Holding AG.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- 89bio.com
News
3 Investable Laggards In An Overbought Market 
My Top 3 Pharma Stocks 
89bio Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB 
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 89bio, Inc. (NASDAQ: ETNB) 
3 Potential Biotech Acquisition Targets 
89BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB 
Deal Dispatch: Need M&A Approval? FCC Chair Explains How To Get It 
Russell 2000 Hits All-Time Highs: 8 Stocks Power Small-Cap Comeback 
12 Health Care Stocks Moving In Thursday's Intraday Session 
Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push
Your note
Sign in to keep a note on ETNB — it syncs with the Stock Master app.